Acute respiratory failure (ARF)
in cancer patients, mechanical ventilation for, 55-56
decelerating flow ventilation effects in, 21-25
extracorporeal life support for, 26-34, 37
incidence, 26
Adjucation strategy, for ventilator-associated pneumonia, 159-163
Airway pressure, in pulmonary stress injury, 58-65
Albumin leak, in acute lung injury, partial liquid ventilation and, 136-139
Angiotensin converting enzyme inhibitor, blood pressure and splanchnic perfusion after cardiac surgery and, 73-79
Angiotensin II, myocardial contractile function and, 42
ANP (atrial natriuretic peptide), myocardial contractile function and, 42
Aortic blood flow, noninvasive measurement of, 177-182
ARF. *See* Acute respiratory failure
Arterial blood gases
ex vivo monitor, clinical trial of, 190-196
with long-term inhaled nitric oxide, 99-102
Atrial natriuretic peptide (ANP), myocardial contractile function and, 42

BB-882, tissue oxygen extraction in endotoxic shock and, 81-89
Blind-protected specimen brush sampling, *vs.* m-BAL, for ventilator-associated pneumonia, 67-71
Blood pressure, after cardiac surgery, enalaprilat and, 73-79
Bolus thermodilution cardiac output, variation of, 184-188
Bradykinin, myocardial contractile function and, 43

Cancer patients, postoperative ARF, mechanical ventilation for, 55-56
Capnometric recirculating gas tonometry (CRGT), of $Pico_2$, 49-54
Cardiac endothelial cells, communciation with myocytes, mediators of, 39-45
Cardiac index, and cerebral blood flow in septic shock, 104-108
Cardiac monitoring, noninvasive, thoracocardiography for, 146-156
Cardiac myocytes, paracrine regulation of, 39-45
Cardiac output, continous. *See* Continuous cardiac output
Cardiac surgery, blood pressure/splanchnic perfusion after enalprilat and, 73-79
CCOmbo catheter, 210
Cerebral blood flow (CBF), and cardiac index in septic shock, 104-108
Children, mechanical ventilation during hyperbaric oxygen therapy, 7-12
Chronic obstructive pulmonary disease (COPD), weaning, optimal pressure support level for, 110-118
CMV (conventional mechanical ventilation), vs. HFOV in pulmonary edema, 126-134
Continous cardiac output (CCO), *vs.* thermodilution technique, 184-188
Continuous cardiac output (CCO)
clinical implications, 204
comparative evaluations, human, 201-203
cost-effectiveness, 204
limitations, 203-204
monitoring device, clinical evaluation of, 91-94
Continuous cardiac output (CCO) (*Continued*)
principle, 198-199
safety/accuracy in animal models, 200-201
technique, 199
troubleshooting, 204, 205
in vitro validation, 199-200
Continuous lateral rotational therapy (CLRT), for lung mucus transport, 119-124
Conventional mechanical ventilation (CMV), vs. HFOV in pulmonary edema, 126-134
COPD (chronic obstructive pulmonary disease), weaning, optimal pressure support level for, 110-118
C-reactive protein (CRP), with long-term inhaled nitric oxide, 99-102
Creatinine clearance, with long-term inhaled nitric oxide, 99-102
CRTG (capnometric recirculating gas tonometry), of $Pico_2$, 49-54

Diaphragm, during COPD weaning, optimal pressure support level and, 110-118
Dobutamine, high dosages, detrimental effects on gastric pHi, 214-215
Dopamine, -induced tissue extravasation, phentolamine prevention of, 13-20

Echo-Doppler Dynemo 3000 system, for aortic blood flow measurement, 177-182
ECLS (extracorporeal life support), for acute respiratory failure, 26-34, 37
Enalaprilat, blood pressure and splanchnic perfusion after cardiac surgery and, 73-79
End-inspiratory pressure, limitation in ARF treatment, 26-34
End-of-life resuscitation preferences, patient-surrogate agreements and, 140-145
Endothelin-1 (ET-1)
myocardial contractile function and, 41
vascular response to sepsis and, 169-175
Endotoxic shock, tissue oxygen extraction, BB-882 and, 81-89
Esophageal echo-Doppler system, for aortic blood flow measurement, 177-182
ET-1. *See* Endothelin-1
Extracorporeal life support (ECLS), for acute respiratory failure, 26-34, 37

Gas exchange, in refractory septic shock, methylene blue and, 164-167
Gastric intramucosal Pco_2 ($Pico_2$), as acute hemorrhage marker, 49-54
Gastric intramucosal pH, dobutamine dosages and, 214-215

HBO_2 (hyperbaric oxygen therapy), for children, mechanical ventilation during, 7-12
Hemodynamics. *See also specific hemodynamic factors*
after cardiac surgery, ACE inhibition and, 73-79
in ARF, decelerating flow ventilation effects on, 21-25
in endotoxic shock, BB-882 and, 81-89
with long-term inhaled nitric oxide, 97-102
in refractory septic shock, methylene blue and, 164-167
of vascular response to sepsis, 169-175

Hemorrhage, acute, $Pico_2$ as quantitative marker for, 49-54
Hexamethonium, effects on vascular response to sepsis, 169-175
High-frequency oscillatory ventilation (HFOV), *vs.* CMV in pulmonary edema, 126-134
Hyperbaric oxygen therapy (HBO_2), for children, mechanical ventilation during, 7-12
Hypoperfusion
  CBF proportionality with cardiac index in, 104-108
  $Pico_2$ as quantitative marker for, 49-54

Inverse ratio ventilation, in acute respiratory failure treatment, 26-34

Left ventricular stroke volume, noninvasive monitoring of, 146-156
Lung mucus transport, continuous lateral rotational therapy for, 119-124

m-BAL (mini-bronchoalveolar lavage), *vs.* b-PSB for ventilator-associated pneumonia, 67-71
Mechanical ventilation
  of children during hyperbaric oxygen therapy, 7-12
  CLRT for lung mucus transport in, 119-124
  conventional, vs. HFOV in pulmonary edema, 126-134
  for postoperative ARF in cancer patients, 55-56
  weaning, optimal pressure support level for, 110-118
Methylene blue, for refractory septic shock, 164-167
Mini-bronchoalveolar lavage (m-BAL), *vs.* b-PSB for ventilator-associated pneumonia, 67-71
Mixed venous oxygen saturation. *See* Svo_2 continuous monitoring
Myocardial desensitizing agent, myocardial contractile function and, 43

Neuromuscular blockers, for tracheal intubation facilitation, 1-5
Nitric oxide (NO)
  long-term inhaled, metabolic fate of, 97-102
  myocardial contractile function and, 40-41
  vasorelaxation and, 39
Nitric oxide synthase inhibitor, for refractory septic shock, 164-167
NO. *See* Nitric oxide

Oxygenation, in pulmonary edema, HFOV and CMV for, 126-134

Paracrine regulation, of cardiac myocytes in normal and septic heart, 39-45
Partial liquid ventilation, albumin leak in acute lung injury and, 136-139
Patient-surrogate agreements, for end-of-life resuscitation preferences, improvement of, 140-145
PEEP. *See* Positive end-expiratory pressure
Phentolamine, for prevention of dopamine-induced tissue extravasation, 13-20
$Pico_2$ (gastric intramucosal Pco_2), as acute hemorrhage marker, 49-54
Platelet-activating factor antagonist, tissue oxygen extraction in endotoxic shock and, 81-89
Pneumonia, ventilator-associated. *See* Ventilator-associated pneumonia
Positive end-expiratory pressure (PEEP)
  for pulmonary edema, 126
  titration, in acute respiratory failure treatment, 26-34
Pressure-controlled ventilation, for acute respiratory failure, 21-25
Pressure-regulated volume-controlled ventilation (PRVC), for acute respiratory failure, 21-25
Prostaglandin E_2, myocardial contractile function and, 41-42
Prostaglandin I_2, myocardial contractile function and, 41-42
Prostanoids, myocardial contractile function and, 41-42
PRVC (pressure-regulated volume-controlled ventilation), for acute respiratory failure, 21-25
Pulmonary artery pressure, in pulmonary stress injury, 58-65
Pulmonary capillary pressure, in pulmonary stress injury, 58-65
Pulmonary edema, volume recruitment and oxygenation in, 126-134
Pulmonary stress injury, airway and vascular pressures in, 58-65

Ranitidine, *vs.* sucralfate, for VAP adjucation, 159-163

Sepsis
  paracrine regulation of cardiac myocytes in, 43-45
  vascular response, neurosympathetic pathways in, 169-175
Septic shock
  CBF proportionality with cardiac index in, 104-108
  refractory, methylene blue for, 164-167
Splanchnic dysoxia, $Pico_2$ as quantitative marker for, 49-54
Splanchnic perfusion, after cardiac surgery, enalaprilat and, 73-79
Succinylcholine, for tracheal intubation facilitation, 1-5
Sucralfate, vs. ranitidine, for VAP adjucation, 159-163
SUPPORT intervention, patient-surrogate agreements and, 140-145
Svo_2 continuous monitoring
  accuracy, evaluation of, 206-207
  clinical applications, 206-209
  cost-effectiveness, 209-210
  future developments, 210
  limitations, 206
  principle of, 205
  technique, 205-206
  troubleshooting, 209

Thoracocardiography, of left ventricular stroke volume, 146-156
Tissue oxygen extraction, in endotoxic shock, BB-882 and, 81-89
Tracheal intubation, facilitation, neuromuscular blockers for, 1-5
Transport, to HBO_2 chamber, problems of mechanically ventilated children and, 7-12

Ventilator-associated pneumonia (VAP)
  adjucation strategy for, 159-163
  m-BAL *vs.* b-PSB for, 67-71
Volume recruitment, in pulmonary edema, HFOV and CMV for, 126-134